G
abapentin is an antiepileptic agent approved by the FDA in 1993 for the adjunctive therapy of partial seizures with or without secondary generalization. Despite being indicated only for the adjunctive treatment of seizures, utilization of gabapentin has increased markedly since its introduction.
The National Institute for Health Care Management reported that gabapentin was the 17th-ranked drug in terms of expenditures in 2000 and the top-selling anticonvulsant. They also reported a 63.3% increase in annual sales from 1999 to 2000 and a 45.9% increase in prescription volume. 1 These are among the largest increases reported for the top 50 drugs. Similar trends are noted in the Oregon Health Plan (OHP), Oregon' s Medicaid program. In 2001, gabapentin was listed in the top-10 drug products by total cost for the fee-for-service Oregon Medicaid program.
The rise in the number of prescriptions and drug spending for gabapentin is not attributed solely to its use as an anticonvulsant. In fact, much has been published on the off-label use of gabapentin, particularly in psychiatric disorders and chronic pain syndromes. Many of these studies, however, are open-label or case studies and do not offer adequate evidence for the off-label use of gabapentin. A limited number of randomized controlled trials are available and have been summarized in Table 1 .
Currently, there is little published information available regarding how gabapentin is being used in clinical practice. Due to the widespread and growing use of this drug, it is important to assess utilization patterns. The objective of this study was to evaluate the use of gabapentin in a primary care setting to determine the following: (a) conditions being treated, (b) specialties of the prescribers, (c) dose ranges, and (d) extent of documentation of follow-up care, monitoring, and evidence of effectiveness.
■■ Methods

Study Design
This study involved a retrospective review of both reimbursement claims data and patient medical charts. Subjects included in the study were identified from CareOregon and Oregon Medicaid feefor-service drug claim databases. CareOregon is a contracted OHP managed care organization that primarily serves Medicaid recipients. These databases capture basic demographic information as well as drug claim information from prescriptions dispensed at Oregon pharmacies. Chart review and data collection were conducted by a clinical pharmacist. A data-collection form was developed and tested on a sample population. Information gathered by the form included patient demographics, prescriber information, indications for gabapentin use, secondary diagnoses, duration of use, reasons for discontinuation, and follow-up information. 
Study Population
The study population was limited to those who were continuously eligible for the OHP and enrolled in CareOregon during the entire study period. A total of 4,638 patients were continuously eligible and enrolled in CareOregon during this period. To be included in the retrospective chart review, patients must have had at least one drug claim for gabapentin in the 33-month period between January 1, 1998, and September 30, 2000. In addition, participants must have been patients at one of 4 Oregon Health and Science University primary care clinics (3 family medicine, 1 internal medicine). A pool of 29 physicians, 42 residents, 3 nurse practitioners, and 1 physician assistant attend patients at these clinics. Exclusion criteria included disenrollment from the OHP and inability to access the patient chart or electronic medical record.
Patient confidentiality was maintained as data were collected, entered into an Access database, and verified by the clinical pharmacist. Descriptive statistics were used for analysis. The study was approved by the Oregon Health and Science University Institutional Review Board (Human Subjects Committee).
■■ Results
Demographics
A total of 105 patients met the eligibility criteria, and all were reviewed. Patients ranged in age from 22 to 83 years (mean 50.3 years; SD 12.9) and were predominantly female (73% versus 27% male); 81% were classified as Caucasian, 8.6% African American, 6.6% Hispanic, and 3.8% Asian. Table 2 summarizes the indications for use of gabapentin within this study population. Ninety-five percent of patients were receiving gabapentin for an off-label indication. Various chronic pain conditions accounted for the majority of gabapentin use (71.4%). Mental health disorders accounted for 15% of the gabapentin use, with bipolar disorder being the most common. Seizure disorders only accounted for 5% of gabapentin use.
Utilization
Prescriber information is outlined in Table 3 . Therapy was initiated by primary care providers 45% of the time compared to 46% started by specialists. While 59% of patients continued to have involvement by the initial prescriber, often there was a shift of care. Specialists appeared to be less involved with maintenance prescribing of gabapentin. Dosing of gabapentin was inconsistent. There was a wide range of prescribed doses both between and within each indication, as demonstrated in Table 4 . Only 47% of patients received gabapentin 3 times daily, the usual dosing frequency. Other patients received the drug once daily (26%), twice daily (18%), or 4 times daily (9%).
After the initiation of gabapentin therapy, 40% (n=42) of patients had no documented follow-up related to the drug. Only 12% (n=13) of the study patients had a documented efficacious response. Any positive statement, regardless of how subjective, was included as a response to the medication. A summary of these patients is presented in Table 5 . The average dose for those patients where a positive response was documented was 1,770 mg (range=300 mg-4,800 mg). The average duration of therapy for these patients was 24.8 months, with 11 of the 13 patients remain- 
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Epilepsy
(5)
Restless leg 3 (3)
Multiple sclerosis 3 (3)
Anxiety
(2)
Behavior disorders 2 (2)
Other 4 (4) ing on therapy at the end of the study period. As expected, most patients were receiving ongoing treatment for either chronic neuropathic pain or epilepsy and were using at least one other medication for the same purpose. By the end of the study period, 68 patients (65%) had discontinued therapy. The average duration of therapy for patients who discontinued gabapentin was 4.2 months (range=1 day to 4 years). The most prominent documented reason for discontinuation was lack of efficacy (43%; n=29), followed by adverse effects (12%; n=8), nonadherence (10%; n=7), and symptom resolution (1%; n=1). In 34% (n=23) of patients, the reason for discontinuation was not documented.
The total cost of drug therapy for all 105 patients during the study period was $1,198,613 ($11,415 per patient). An average of $1,123 was spent per patient on gabapentin alone, or about 10% of the total cost of drug therapy. Patients who were labeled as responders had a higher average gabapentin expenditure of $3,095 per patient.
■■ Discussion
Little clinical trial data exist (Table 1) to support the use of gabapentin in many of the conditions being treated in this study. Due to a lack of clinical trial data, there are no dosing or therapeutic guidelines to direct the use of gabapentin. Information that does exist is primarily based on case reports and a few open-label trials. While such reports are valuable for directing further research, they are generally not sufficient as the basis of treatment decisions.
In this study, gabapentin was largely used for a variety of pain syndromes. Clinical trials of gabapentin support its efficacy in selected neuropathic pain syndromes. Specifically, gabapentin is efficacious for the treatment of diabetic neuropathy and postherpetic neuralgia, especially when high doses are used. 2, 3 Data are lacking for other types of chronic pain conditions. To date, only one controlled trial has been published comparing gabapentin to tricyclic antidepressants in the treatment of diabetic neuropathy.
Tricyclic antidepressants are generally considered first-line therapy, although toxicity in overdose is considered a disadvantage. Gabapentin and amitriptyline appear to be comparable in efficacy and tolerability for the treatment of diabetic neuropathy, 4 but the effective dose of gabapentin has an average wholesale price of $191 per month compared to $7 per month for amitriptyline.
There are two published randomized controlled trials that studied the use of gabapentin in migraine prophylaxis. In the first study, gabapentin failed to demonstrate efficacy greater than placebo. 5 A second study reported efficacy with gabapentin for the prevention of migraine when compared to placebo. 6 The American Academy of Neurology cites both of these studies in its published guidelines for the prophylaxis of migraines. The AAN guidelines maintain that there is limited evidence for the use of gabapentin in clinical practice. 7 Studies of gabapentin in psychiatric disorders have ranged from anxiety and social phobia to affective disorders and drug dependence. Only two randomized trials have been published that evaluate the use of gabapentin monotherapy in bipolar disorder. Both failed to demonstrate efficacy superior to placebo. 8, 9 Similarly, Pande et al. evaluated the use of gabapentin in the treatment of panic disorder and failed to show a difference from placebo in the Panic and Agoraphobia Scale. 10 For other psychiatric indications (e.g., anxiety, obsessive-compulsive disorder, drug and alcohol withdrawal), randomized controlled trials are lacking.
This retrospective chart review found that gabapentin was being used almost exclusively for off-label indications in the population reviewed. Unfortunately, it appeared that relatively few patients benefited from treatment based on information documented in the medical record. Although gabapentin was being used for chronic conditions, only a small number of patients remained on therapy at the end of the study period.
It is interesting to speculate as to why gabapentin was being used for such a wide variety of off-label indications. First, marketing may have played a role. The manufacturer of gabapentin has been accused of aggressively promoting the drug for off-label indications due to the limited market for seizure disorders. 11 Second, patients with chronic pain and/or mood disorders can be difficult to manage. Gabapentin may be viewed as a treatment option that has relatively few serious side effects and drug interactions, reasonable tolerance, and is fairly easy to prescribe. Clinicians may be hoping for a positive response while minimizing the risk of harm.
The pattern of gabapentin use documented in this study does not appear to represent the best use of health care resources. Health plans might want to consider options to promote more cost-effective use of gabapentin. Prior authorization is one option. Criteria could be developed to approve the use of gabapentin for off-label diagnoses where clinical trial data support its efficacy. Mandatory follow-up could also be considered to ensure an appropriate therapeutic response after 2 or 3 months of treatment, before long-term use is approved. Educational interventions such as academic detailing might also help promote the appropriate use of gabapentin.
There are a couple of important limitations to interpreting this study. First, we studied a Medicaid population at one academic institution. These results may not generalize to other settings. Additional studies are needed to confirm our findings. Second, data were obtained only from the review of patient medical records and reimbursement claims data. We did not collect information directly from patients or providers. Thus, definitive conclusions regarding effectiveness of gabapentin for various conditions cannot be drawn from our data. There is a tremendous need for clinical trials to better define the role of gabapentin in a variety of conditions for which it is currently being prescribed.
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■■ Conclusion
This retrospective review demonstrated that gabapentin is prescribed for a wide variety of conditions. Almost all patients (95%) received gabapentin for off-label diagnoses. The use of gabapentin in many of these patients is not supported by evidence from randomized clinical trials. Most patients did not appear to benefit from gabapentin therapy, and many patients did not appear to receive adequate follow-up once gabapentin was started. 
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